United States - English - NLM (National Library of Medicine)

la jolla pharmaceutical company - angiotensin ii (unii: m089efu921) (angiotensin ii - unii:m089efu921) - angiotensin ii 2.5 mg in 1 ml - giapreza increases blood pressure in adults with septic or other distributive shock [see clinical studies (14)] . none. risk summary the published data on angiotensin ii use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. animal reproduction studies have not been conducted with giapreza. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk septic or other distributive shock is a medical emergency that can be fatal if left untreated. delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to incr

European Union - English - EMA (European Medicines Agency)

paion deutschland gmbh - angiotensin ii acetate - hypotension; shock - agents acting on the renin-angiotensin system - giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.riprazo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rirpozo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.sprimeo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.sprimeo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

bio concepts pty ltd - piper methysticum, quantity: 400 mg (equivalent: piper methysticum, qty 3.2 g; equivalent: kavalactones (of piper methysticum), qty 50 mg); magnesium amino acid chelate, quantity: 250 mg (equivalent: magnesium, qty 50 mg); melissa officinalis, quantity: 75 mg (equivalent: melissa officinalis, qty 750 mg); ziziphus jujuba var. spinosa, quantity: 300 mg (equivalent: ziziphus jujuba var. spinosa, qty 3 g); glycine, quantity: 100 mg; magnolia officinalis, quantity: 150 mg (equivalent: magnolia officinalis, qty - tablet, film coated - excipient ingredients: magnesium stearate; carnauba wax; maltodextrin; microcrystalline cellulose; acacia; povidone; macrogol 8000; hypromellose; calcium hydrogen phosphate dihydrate; crospovidone; colloidal anhydrous silica; purified water - maintain/support general health and wellbeing ; traditionally used in pacific islander medicine to decrease/reduce/relieve mild joint aches and pains ; traditionally used in western herbal medicine to decrease/reduce/relieve flatulence/carminative ; traditionally used in western herbal medicine to decrease/reduce/relieve abdominal bloating/distention ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of indigestion/dyspepsia ; traditionally used in western herbal medicine to relieve digestive discomfort ; traditionally used in pacific islander medicine to maintain/support muscle relaxation ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; traditionally used in pacific islander medicine to decrease/reduce/relieve symptoms of stress (linked indication:decrease/reduce/relieve disturbed/restless sleep; maintain/support healthy sleeping patterns); traditionally used in western her